biogen idec

Pipeline

Molecule: Anti-CD23 (lumiliximab)
Potential Effect: Monoclonal antibody. Promotes killing of CD-23-bearing cells. CD-23 cells are commonly found in Chronic Lymphocytic Lymphoma
Lead Indications: Chronic Lymphocytic Leukemia

Molecule: Anti-CD80 (galiximab)
Potential Effect: Primatized monoclonal antibody. Promotes killing of activated B-cells of follicular and other non-Hodgkin's lymphomas by binding to their surface and marking them for destruction by the body's immune system
Lead Indications: Non-Hodgkin's Lymphoma

Molecule: Hsp90 Inhibitor
Potential Effect: Inhibits HSP90, which is critical for tumor cell survival
Lead Indications: Solid Tumors

Molecule: LTβR Inhibitor
Potential Effect: Reduces abnormal immune activation in immune mediated inflammatory conditions
Lead Indications: Rheumatoid Arthritis

Molecule: BG-12 Dimethyl Fumarate
Potential Effect: Reduces T-cell inflammatory cytokines, T-cell activation and the number of activated T-cells
Lead Indications: Psoriasis, MS

Molecule: BR3-FC
Potential Effects: Soluble BAFF Antagonist. Inhibits the survival and function of pathogenic B-cells
Lead Indications: Inflammatory disorders (Lupus Nephritis, Sjogrens)

Molecule: V2006/BIIB014
Potential Effect: A novel adenosine A2a receptor antagonist for neurological diseases
Lead Indications: Parkinson's Disease

Molecule: Aviptadil (VIP)
Potential Effect: Vasodilatory, antiproliferative
Lead Indications: Pulmonary Arterial Hypertension

Molecule: CDP 323
Potential Effect: Inhibits VLA4 (oral)
Lead Indications: Multiple Sclerosis

Molecule: FIX:Fc
Potential Effect: fusion protein. Increases plasma levels of Factor IX, the deficient clotting factor, to temporarily correct the coagulation defect.
Lead Indications: Hemophilia

▼ ONCOLOGY

▼ NEUROLOGY AND IMMUNOLOGY

OTHER THERAPEUTIC AREAS ▼

Phase 4
Approved
Filing
Phase 3
Phase 2
Phase 1
Preclinical
Research

Anti-Cripto mAb
Anti-BR3 mAb
Anti-CD23 mAb lumiliximab
Anti-CD80 mAb galiximab
Hsp90 Inhibitor
M200 (volociximab)
Rituxan® (rituximab)
Anti-IGF-1R
CDP 323
Humanized Anti-CD20 mAb
BR3-Fc
Lymphotoxin Beta Receptor
V2006/ BIIB014
Daclizumab
Nogo
Lingo
Rituxan® (rituximab)
Tysabri® (natalizumab)
Avonex®
Neublastin®
Anti-CD40L
Anti-TWEAK
BG-12/Oral Fumarate
Fumaderm
Aviptadil (VIP)
Adentri
Lixivaptan
rFactor IX

Solid tumors
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Non-Hodgkin's B-cell Lymphoma
Solid tumors
Solid Tumors
Chronic Lymphocytic Leukemia
Non-Hodgkin's B-cell Lymphoma
Solid Tumors
Multiple Sclerosis-Relapsing Forms
Rheumatoid Arthritis
Inflammatory Disorders
Rheumatoid Arthritis
Parkinson's Disease
Multiple Sclerosis
Multiple Sclerosis
Multiple Sclerosis
Multiple Sclerosis-Relapsing Forms
Multiple Sclerosis-Primary Progressive
Lupus/SLE
Anti-TNF Refractory Rheumatoid Arthritis
DMARD Refractory Rheumatoid Arthritis
Multiple Sclerosis-Relapsing Forms
Crohn's Disease
Multiple Sclerosis-Relapsing Forms
Neuropathic Pain
Lupus/SLE
Rheumatoid Arthritis
Multiple Sclerosis-Relapsing Forms
Psoriasis
Pulmonary Arterial Hypertension
Congestive Heart Failure
Heart Failure
Hemophilia B

Molecule: Anti-Cripto mAb
Potential Effect: Binds to Cripto and causes intracellular release of maytansine, resulting in cell death
Lead Indications: Solid Tumors

Molecule: M200 (volociximab)
Potential Effect: chimeric monoclonal antibody directed against alpha 5 beta1 integrin. Inhibits angiogenesis necessary for tumor growth
Lead Indications: Solid tumors

Molecule: Anti-BR3
Potential Effect: Humanized monoclonal antibody. Directed against BR3 that may promote killing B-cells by ADCC
Lead Indications: Chronic Lymphocytic Leukemia

Molecule: 2H7v16 (Ocrelizumab)
Potential Effect: A humanized anti-CD20 monoclonal antibody that may induce depletion of circulating B-cells
Lead Indications: Rheumatoid Arthritis

Molecule: Daclizumab
Potential Effect: A humanized monoclonal antibody that binds to the IL-2 receptor
Current indications: Prevention of kidney transplant rejection
Lead Indications: Multiple Sclerosis

Molecule: Neublastin
Potential Effect: Novel neurotrophic protein in GDNF family
Lead Indications: Neuropathic pain

Molecule: Nogo
Potential Effects: Triggers regeneration of nerves
Lead Indications: Multiple Sclerosis

Molecule: Lingo
Potential Effect: Repairs the myelin shield of the nerve cells
Lead Indications: Multiple Sclerosis

Molecule: Adentri
Potential Effects: Adenosine receptor antagonist. Blocks adenosine receptors in the kidney which are clinically relevant for the treatment of congestive heart failure
Lead Indications: Cardiology